EUVIMEDEUVIMED entdecken
Open Access

Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

Xinyu Hu iD, Dan Li iD, Weijie Chen, Hongyu Kuang iD, Dan Yang iD, Zhiyan Gong, Yuxiang Long iD, Guangliang Liu iD, Kai Wang, Mengshi Xia, Yanping Xu iD, Yuehui Yin iD

Journal of the American Heart Association · 19.08.2025 · 14 (16)

DOI: 10.1161/jaha.124.040093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 19.08.2025. Verfasst von Xinyu Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine The Second Affiliated Hospital of Chongqing Medical University Chongqing China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Autophagy, Heart Failure, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with high morbidity and mortality. Empagliflozin, an SGLT2 (sodium–glucose cotransporter 2) inhibitor, reduces adverse events in patients with HFpEF regardless of glycemic control. However, the precise cardioprotective mechanisms of SGLT2 inhibitor in HFpEF remain underexplored. Methods and Results A “2‐hit” mouse model of HFpEF was developed via the high‐fat diet combined with N ω ‐nitro‐L‐arginine methyl ester. Male C57BL/6N mice were assigned to either a control group (n=10) or an HFpEF group (n=20), with the latter receiving empagliflozin (10 mg/kg per day, n=10) or vehicle (n=10) for 8 weeks. Cardiac function, hypertrophy, and fibrosis were evaluated by physiological, biochemical, and histological measurements. Mechanistic analysis, including RNA sequencing, Western blotting, and immunohistochemistry, was conducted. In vitro, H9c2 cardiomyocytes were exposed to angiotensin II and palmitate, followed by empagliflozin treatment. In vivo, empagliflozin treatment improved body weight, blood pressure, glucose tolerance, and reduced cardiac hypertrophy, fibrosis, and diastolic dysfunction in HFpEF mice. Mechanistic analysis revealed that empagliflozin modulated the AMPK (AMP‐activated protein kinase)/mTORC1 (mammalian target of rapamycin complex 1)/autophagy signaling pathway. Specifically, empagliflozin restored the autophagy markers (Beclin1 and LC3‐II [microtubule‐associated protein 1 light chain 3]) and altered the phosphorylation of AMPK, mTOR, and p70S6K (ribosomal protein S6 kinase beta‐1). Inhibition of AMPK or autophagy nullified the antihypertrophic effect of empagliflozin, underscoring the dependence on the AMPK/mTORC1/autophagy pathway.

Conclusions

Empagliflozin effectively ameliorates cardiac remodeling and diastolic dysfunction in HFpEF by enhancing autophagy via the AMPK/mTORC1 pathway. These findings elucidate the direct cardioprotective mechanisms of empagliflozin and suggest potential therapeutic molecular targets for HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAutophagyHeart FailureAMP-Activated Protein KinasesStroke VolumeBenzhydryl CompoundsGlucosidesMechanistic Target of Rapamycin Complex 1Myocytes, CardiacVentricular Function, LeftAnimalsMice, Inbred C57BLDisease Models, AnimalMaleMiceSignal Transduction

Stichwörter der Autor:innen

HFpEFSGLT2 inhibitorautophagycardiac remodelingdiastolic function

Substanzen

Sodium-Glucose Transporter 2 InhibitorsAMP-Activated Protein KinasesempagliflozinBenzhydryl CompoundsGlucosidesMechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine The Second Affiliated Hospital of Chongqing Medical University Chongqing China.
  • Chongqing Key Laboratory of Arrhythmias Chongqing China.
  • Department of Cardiology Chongqing University Fuling Hospital Chongqing China.
  • Chongqing Cardiac Arrhythmias Therapeutic Service Center Chongqing China.
  • Department of Ultrasound Medicine The First Affiliated Hospital of Chongqing Medical University Chongqing China.

ORCID-Profile: Xinyu Hu, Dan Li, Hongyu Kuang, Dan Yang, Yuxiang Long, Guangliang Liu, Yanping Xu, Yuehui Yin

Zitieren

APA

Hu, X., Li, D., Chen, W., Kuang, H., Yang, D., Gong, Z., Long, Y., Liu, G., Wang, K., Xia, M., Xu, Y., & Yin, Y. (2025). Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway. Journal of the American Heart Association, 14(16). https://doi.org/10.1161/jaha.124.040093

Vancouver

Hu X, Li D, Chen W, Kuang H, Yang D, Gong Z, et al. Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway. Journal of the American Heart Association. 2025;14(16). doi:10.1161/jaha.124.040093

BibTeX
@article{Hu2025,
  author = {Hu, Xinyu and Li, Dan and Chen, Weijie and Kuang, Hongyu and Yang, Dan and Gong, Zhiyan and Long, Yuxiang and Liu, Guangliang and Wang, Kai and Xia, Mengshi and Xu, Yanping and Yin, Yuehui},
  title = {Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {16},
  doi = {10.1161/jaha.124.040093}
}
Kostenlos starten →